scholarly journals Transdermal Testosterone Application: Pharmacokinetics and Effects on Pubertal Status, Short-Term Growth, and Bone Turnover

2004 ◽  
Vol 89 (2) ◽  
pp. 681-687 ◽  
Author(s):  
A. Mayo ◽  
H. Macintyre ◽  
A. M. Wallace ◽  
S. F. Ahmed
Keyword(s):  
Bone Turnover ◽  
Bone Age ◽  
Free Testosterone ◽  
Bone Alkaline Phosphatase ◽  
Percentage Change ◽  
Leg Length ◽  
Short Term ◽  
Median Percentage ◽  
Salivary Testosterone ◽  
Acceptable Method

The aim of the study was to assess the effect of transdermal testosterone on free testosterone concentrations in saliva and on short-term growth and bone turnover in boys with growth or pubertal delay. A prospective, randomized, crossover study was conducted over 26 wk with 4 wk of run-in, 8 wk of treatment I (8 or 12 h), 4 wk of washout, 8 wk of treatment II (8 or 12 h), and 4 wk of final washout. The main outcome measures were salivary testosterone profiles during the different study periods; weekly change in lower leg length (LLL) as measured by knemometry, i.e. LLL velocity; absolute and percentage change in bone alkaline phosphatase (bALP) levels; and deoxypyridinoline cross-links measured in urine. Eight boys who took part in the study had a median age of 13.5 yr (range, 12.4–14.9 yr), testicular volume of 3 ml (range, 2–6 ml), height sd score of −2.4 (range, −1.44 to −3.35), and bone age delay of 2 yr (range, 1–3.2 yr). Median salivary testosterone during 8- and 12-h treatments [179 pg/ml (range, 7–3579 pg/ml) and 150 pg/ml (range, 12–3472 pg/ml) (not significant)] was significantly higher than during the run-in and washout blocks (P < 0.0001) [9 pg/ml (range, <7 to 122 pg/ml) and 13 pg/ml (range, <7 to 285 pg/ml) (not significant)]. LLL velocity in the treatment blocks (median, 0.64 mm/wk; range, 0.1–1.08 mm/wk) was significantly higher than during the run-in and washout periods (median, 0.48 mm/wk; range, −0.06 to 0.92 mm/wk) (P < 0.001). The main rise in bALP occurred during the first treatment block with a median percentage change in bALP of 44.2% (range, −4 to 87%) and a smaller percentage change in bALP at the end of the second treatment block of 9.8% (range, −4 to 55%). The increases in bALP were not significantly different between the 8- and 12-h treatment periods, and there was no significant decline during the washout periods. Overnight transdermal testosterone application, as Virormone (5 mg), may be a potentially acceptable method of induction of puberty and stimulates short-term growth and bone turnover.

scholarly journals Epiphysiodesis for the treatment of tall stature and leg length discrepancy

2021 ◽  
Author(s):  
Madeleine Willegger ◽  
Markus Schreiner ◽  
Alexander Kolb ◽  
Reinhard Windhager ◽  
Catharina Chiari
Keyword(s):  
Surgical Planning ◽  
Multidisciplinary Approach ◽  
Treatment Options ◽  
Bone Age ◽  
Leg Length Discrepancy ◽  
Tall Stature ◽  
Complication Rates ◽  
Leg Length ◽  
Growth Prediction ◽  
Length Discrepancy

SummaryPainful orthopedic conditions associated with extreme tall stature and leg length discrepancy (LLD) include back pain and adopting bad posture. After failure of conservative treatment options, blocking of the growth plates (epiphysiodesis) around the knee emerged as gold standard in patients with tall stature and LLD in the growing skeleton. Surgical planning includes growth prediction and evaluation of bone age. Since growth prediction is associated with a certain potential error, adequate planning and timing of epiphysiodesis are the key for success of the treatment. LLD corrections up to 5 cm can be achieved, and predicted extreme tall stature can be limited. Percutaneous epiphysiodesis techniques are minimally invasive, safe and efficient methods with low complication rates. In general, a multidisciplinary approach should be pursued when treating children and adolescents with tall stature.

scholarly journals Short-Term Orlistat Treatment Does Not Affect Mineral Balance and Bone Turnover in Obese Men

2001 ◽  
Vol 131 (6) ◽  
pp. 1694-1699 ◽  
Author(s):  
Daniel G. Pace ◽  
Steven Blotner ◽  
Roberto Guerciolini
Keyword(s):  
Bone Turnover ◽  
Short Term ◽  
Mineral Balance

The prevalence of low serum free testosterone and the short-term effect of anti-retroviral therapy in male Japanese treatment-naïve HIV patients

2019 ◽  
Vol 25 (4) ◽  
pp. 318-321 ◽  
Author(s):  
Yusuke Yoshino ◽  
Ichiro Koga ◽  
Keita Misu ◽  
Kazunori Seo ◽  
Takatoshi Kitazawa ◽  
...  
Keyword(s):  
Free Testosterone ◽  
Term Effect ◽  
Short Term ◽  
Hiv Patients ◽  
Serum Free ◽  
Short Term Effect ◽  
Treatment Naïve ◽  
Low Serum

Testosterone Need Questioned

PEDIATRICS ◽  
1983 ◽  
Vol 71 (4) ◽  
pp. 666-667
Author(s):  
RON G. ROSENFELD ◽  
RAYMOND L. HINTZ
Keyword(s):  
Linear Growth ◽  
Bone Age ◽  
General Linear ◽  
Short Term ◽  
Testosterone Treatment ◽  
Significant Growth ◽  
Significant Difference ◽  
Constitutional Delay ◽  
Study Population

In Reply.— We thank Dannenhoffer and Crawford for their thoughtful comments on our recent study of testosterone treatment of constitutional delay. We agree that the size of the study population was relatively small, and that subject randomization resulted in a significant difference in mean height at the time of entry into the study. Nevertheless, we believe the data still support the conclusion that short-term testosterone treatment can result in significant growth acceleration in this population. In general, linear growth in children correlates better with bone age than with chronologic age, and the skeletal ages of the two groups in this study were not significantly different.

Salivary Free Testosterone in Hirsutism

1989 ◽  
Vol 26 (6) ◽  
pp. 522-526 ◽  
Author(s):  
Joško Osredkar ◽  
Ivan Vrhovec ◽  
Niko Jesenovec ◽  
Andreja Kocijančič ◽  
Janez Preželj
Keyword(s):  
Serum Testosterone ◽  
Free Testosterone ◽  
Human Saliva ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Dehydroepiandrosterone Sulphate ◽  
Hormone Binding ◽  
Salivary Testosterone ◽  
Diagnostic Use

A sensitive, specific and accurate direct radioimmunoassay of testosterone in human saliva is described. A single salivary testosterone result is shown to be of greater diagnostic use in hirsutism than any of the currently used serum androgen assays. Thus, of 50 hirsute patients, salivary testosterone (Sa-T) was elevated in 34 patients, sex hormone-binding globulin (SHBG) was decreased in 30 women, serum testosterone (S-T) elevated in 13, dehydroepiandrosterone sulphate (DHEA-S) was elevated in 14, and androstenedione in three of the investigated group.

scholarly journals Persistent Increase in Bone Turnover in Graves’ Patients with Subclinical Hyperthyroidism

2000 ◽  
Vol 85 (11) ◽  
pp. 4157-4161 ◽  
Author(s):  
Yasuro Kumeda ◽  
Masaaki Inaba ◽  
Hideki Tahara ◽  
Yasuko Kurioka ◽  
Tetsuro Ishikawa ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Bone Metabolism ◽  
Antithyroid Drug ◽  
Significant Negative Correlation ◽  
Bone Alkaline Phosphatase ◽  
Mineral Density ◽  
Free T4 ◽  
Bone Formation Markers ◽  
Significant Attenuation ◽  
Group B

Hyperthyroid patients exhibit accelerated bone loss by increased bone turnover, and normalization of thyroid function is associated with a significant attenuation of increased bone turnover, followed by an increase in bone mineral density. However, of patients with Graves’ disease (GD) maintained on antithyroid drug (ATD) treatment, some exhibit persistent suppression of TSH long after normalization of their serum free T3 (FT3) and free T4 (FT4) levels. The aim of this study was to examine whether bone metabolism is still enhanced in TSH-suppressed premenopausal GD patients with normal FT3 and FT4 levels after ATD therapy (n = 19) compared with that in TSH-normal premenopausal GD patients (n = 30), and to evaluate the relationship between serum TSH receptor antibody (TRAb), an indicator of disease activity of GD, and various biochemical markers of bone metabolism. No difference was found between the two groups in serum Ca, phosphorus, or intact PTH, or in urinary Ca excretion. Serum bone alkaline phosphatase (B-ALP), bone formation markers, and urinary excretions of pyridinoline (U-PYD) and deoxypyridinoline (U-DPD), which are bone resorption markers, were significantly higher in the TSH-suppression group than in the TSH-normal group (B-ALP, P < 0.05; U-PYD, P < 0.001; U-DPD, P < 0.001). For the group of all GD patients enrolled in this study, TSH, but neither FT3 nor FT4, exhibited a significant negative correlation with B-ALP (r = −0.300; P < 0.05), U-PYD (r= −0.389; P < 0.05), and U-DPD (r = −0.446; P < 0.05), whereas TRAb exhibited a highly positive and significant correlation with B-ALP (r = 0.566; P < 0.0001), U-PYD (r = 0.491; P < 0.001), and U-DPD (r = 0.549; P < 0.0001). Even in GD patients with normal TSH, serum TRAb was positively correlated with B-ALP (r = 0.638; P < 0.001), U-PYD (r = 0.638; P < 0.001), and U-DPD (r = 0.641; P < 0.001). In conclusion, it is important to achieve normal TSH levels during ATD therapy to normalize bone turnover. TRAb was not only a useful marker for GD activity, but was also a very sensitive marker for bone metabolism in GD patients during ATD treatment.

Sign in / Sign up

Export Citation Format

Share Document